TY - JOUR T1 - Longitudinal Changes in COVID-19 Associated In-Hospital Mortality JF - medRxiv DO - 10.1101/2021.05.04.21255938 SP - 2021.05.04.21255938 AU - Frederick Warner AU - Matt D.T. Hitchings AU - Derek A.T. Cummings AU - Jacob McPadden AU - Harlan M. Krumholz AU - Albert I. Ko AU - Wade L. Schulz Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/04/2021.05.04.21255938.abstract N2 - Objective As the COVID-19 pandemic has evolved, a key question for health care systems is whether in-hospital mortality has changed over time and if so, what factors contributed to these changes. Our goal was to leverage real-world data spanning two COVID-19 surges over the first year of the pandemic to determine the temporal trend of in-hospital mortality.Design This was an observational, retrospective study based on real-world data for patients admitted with COVID-19. Generalized additive models (GAM) were used to evaluate the association of covariates with the composite outcome over time.Setting and Population We identified a retrospective cohort of all patients who were hospitalized within the Yale New Haven Health (YNHH) system with an admission diagnosis of COVID-19 between March 1, 2020 and February 28, 2021.Main outcome The primary outcome for the study was a composite endpoint of in-hospital mortality, defined as death during the index hospitalization or discharge to hospice.Results Among 6,477 discharges over the study period, the mean age was 66.2 years (SD=17.6), 52.5% (n=3,401) were male and the overall composite mortality was 14.2% (n=920). Composite in-hospital mortality was significantly associated with increased age, comorbidity index, respiratory rate, and heart rate; decreased systolic blood pressure; male sex; and admission from a long-term care facility (LTCF). The significant temporal decrease in mortality that was observed for patients admitted from a location other than a LTCF was not seen in those admitted from a LTCF.Conclusions We found that the adjusted in-hospital mortality rate declined over the first year of the pandemic, despite a second surge in COVID-19-related hospitalizations. Importantly, the decrease in mortality appeared to be driven by declines in risk in those not admitted from a LTCF. The observed decrease in mortality over time suggests that improved outcomes may be due to progressive, incremental learning and continuous evolution in hospital practice and policy over the course of the pandemic.Competing Interest StatementA.I.K. reports grants from Bristol Myer Squib, grants from Regeneron, grants from Serimmune, grants and personal fees from Tata Medical Devices outside the submitted work. H.M.K. works under contract with the Centers for Medicare & Medicaid Services to support quality measurement programs, was a recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Martin Baughman Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a member of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is the co-founder of Hugo Health, a personal health information platform, and cofounder of Refactor Health, a healthcare AI-augmented data management company. W.L.S. was an investigator for a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; is a technical consultant to Hugo Health, a personal health information platform; cofounder of Refactor Health, an AI-augmented data management platform for healthcare; and was a consultant for Interpace Diagnostics Group, a molecular diagnostics company. The other authors have no relevant disclosures.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Yale University Institutional Review Board (IRB #2000027975).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData cannot be shared publicly because of the presence of potentially identifiable health information. Requests for access can be directed to the corresponding author and Yale Human Research Protection Program (hrpp@yale.edu). ER -